Emcure Pharmaceuticals Ltd.
NSE: EMCUREEmcure Pharmaceuticals Ltd.: A 30-second snapshot
Emcure trades at Rs 1,906.2, up 36.18% over the past 12 months and 12.77% over the past 3 months, sitting 2.74% below its 52-week high and above both its 50-day (Rs 1,795.67) and 200-day (Rs 1,566.45) moving averages. Trailing PE of 39.12x ranks 3rd of 6 among listed pharma peers, alongside ROE of 19.57% held above 15% in 4 of the last 5 years and a debt-to-equity ratio of roughly 0.31 on a falling trend. Recent news flow (8 items, all classified positive) centered on a CDSCO nod for Poviztra in MASH/liver-fibrosis treatment and a Rs 231.87 crore agreement to acquire full control of Gennova Biopharmaceuticals.
P/E
39.1
Forward P/E
25.2
ROE
+19.6%
Debt / Equity
30.57
Profit Margin
+10.0%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
78/100
News
8 headlines · 8 positive · 0 negative
Emcure to expand use of Poviztra for MASH indication after CDSCO nod - Express Pharma
Express Pharma
Emcure Pharmaceuticals gets India nod for MASH treatment in adults with liver fibrosis - CNBC TV18
CNBC TV18
Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment - The Economic Times
The Economic Times
Emcure gets CDSCO approval for using Povizta for liver disease treatment - ANI News
ANI News
Emcure Pharma to Invest ₹231.87 Crore to Acquire 100% Control of Gennova Biopharmaceuticals - Sahi
Sahi
Recent context
- ·CDSCO approved expanded use of Poviztra for the MASH (metabolic dysfunction-associated steatohepatitis) indication in adults with liver fibrosis, reported across Express Pharma, CNBC TV18, The Economic Times, and ANI News between July 14-20, 2026.
- ·The company agreed to invest Rs 231.87 crore to acquire 100% control of Gennova Biopharmaceuticals, per a July 14, 2026 report.
- ·All 8 tracked news items over the period were classified positive; no negative items appeared in the current sample.
Strengths
- +ROE of 19.57% has stayed above 15% in 4 of the last 5 years, with a persistence/consistency score of 98 and positive free cash flow in 4 of the last 5 years.
- +Debt-to-equity of roughly 0.31 is on a falling trend, pointing to a comparatively unlevered balance sheet.
- +Stock is up 36.18% over 12 months and 12.77% over 3 months, trading above both its 50-DMA and 200-DMA with an RSI of 59.98 (neutral, not overbought).
- +Ranks 2nd of 6 sector peers on ROE and on quality score, and 3rd of 6 on trailing PE.
Weaknesses
- −Trailing PE of 39.12x is about 55% above the forward PE of 25.24x, so the current multiple already prices in a comparably large increase in near-term earnings.
- −Profit margin of 10.04% is on the thinner side relative to the 16.7% five-year revenue growth and 28.8% five-year earnings growth already reported.
- −Analyst consensus of 1.43 (1-5 scale, lower = more constructive) is drawn from a panel of only 7 analysts, a small sample relative to large-cap peers.
- −1-year price-change data is unavailable for all 5 listed sector peers, limiting how reliably momentum can be benchmarked within the sector.
Open questions
- ?Does the roughly 55% gap between trailing and forward PE reflect a specific, disclosed earnings catalyst such as the Poviztra approval, or a broader re-rating expectation?
- ?How might the Gennova Biopharmaceuticals acquisition change Emcure's balance sheet and debt-to-equity trajectory relative to its current falling-debt trend?
- ?What would need to change in cost structure or product mix for profit margins (currently 10.04%) to catch up with the faster revenue and earnings growth already reported?
- ?With the stock only 2.74% below its 52-week high and near the Rs 1,944 resistance level, what has historically driven Emcure's price action at similar technical junctures?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| EMCURE | Emcure Pharmaceuticals Ltd.You're viewing | 39.1 | +19.6% | 54 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 42.1 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.8 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.8 | +8.8% | 4 |
Technical state
Current price
₹1,906.20
SMA 50
₹1,795.67
SMA 200
₹1,566.45
RSI (14)
60.0 (neutral)
From 52w high
-2.7%
1Y return
+36.2%
3M return
+12.8%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumTrailing PE of 39.12x is about 55% above the forward PE of 25.24x, meaning the current multiple already prices in a comparably large increase in near-term earnings; a shortfall against that embedded growth expectation would pressure the multiple.
- lowProfit margin of 10.04% converts 5-year revenue growth of 16.7% into a comparatively modest bottom-line outcome relative to the scale of earnings growth reported (28.8% over 5 years).
- lowAnalyst consensus rating of 1.43 (1-5 scale, lower = more constructive) is based on a panel of only 7 analysts, a small sample size relative to large-cap coverage norms.
- low1-year price-change data is unavailable for all 5 listed sector peers (APOLLOHOSP, CIPLA, DRREDDY, MAXHEALTH, SUNPHARMA), preventing a like-for-like momentum comparison within the sector ranking.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days